Managing prolactin-secreting adenomas during pregnancy

Canadian Family Physician

Volumn 53, Issue 4, 2007, Pages 653-658

  Imran, Syed Ali ^a,b   Ur, Ehud ^b   Clarke, David B ^c  

^a Halifax Neuropituitary Program   (Canada)

^b Division of Endocrinology and Metabolism   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; PROLACTIN; QUINAGOLIDE;

ABORTION; ADULT; ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISEASE SEVERITY; ECTOPIC PREGNANCY; ENDOCRINE SURGERY; FEMALE; FETUS MALFORMATION; GENERAL PRACTITIONER; HUMAN; HYPERPROLACTINEMIA; MEDICAL LITERATURE; MEDICAL SPECIALIST; MULTIPLE PREGNANCY; PATIENT REFERRAL; PREGNANCY; PREGNANT WOMAN; PREMATURE LABOR; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SPONTANEOUS ABORTION; TERTIARY HEALTH CARE;

ADULT; BROMOCRIPTINE; FEMALE; HUMANS; MONITORING, PHYSIOLOGIC; PHYSICIANS, FAMILY; PITUITARY NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; PRENATAL CARE; PROGNOSIS; PROLACTINOMA; RISK ASSESSMENT;

EID: 34247497320     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Melmed S, Braunstein GD, Chang RJ, Becker DP. Pituitary tumors secreting growth hormone and prolactin. Ann Intern Med 1986;105:238-53.
2. Kredentser JV, Hoskins CF, Scott JZ. Hyperprolactinemia - a significant factor in female infertility. Am J Obstet Gynecol 1981;139:264-7.
3. Greer ME, Moraczewski T, Rakoff JS. Prevalence of hyperprolactinemia in anovulatory women. Obstet Gynecol 1980;56:65-9.
4. Elster AD, Sanders TG, Vines FS, Chen MY. Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging. Radiology 1991;181:531-5.
5. Miki Y, Asato R, Okumura R, Togashi K, Kimura I, Kawakami S, et al. Anterior pituitary gland in pregnancy: hyperintensity at MR. Radiology 1993;187:229-31.
6. Dinc H, Esen F, Demirci A, Sari A, Resit Gumele H. Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol 1998;39:64-9.
7. Goluboff LG, Ezrin C. Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis. J Clin Endocrinol Metab 1969;29:1533-8.
8. Vician L, Shupnik MA, Gorski J. Effects of estrogen on primary ovine pituitary cell cultures: stimulation of prolactin secretion, synthesis, and preprolactin messenger ribonucleic acid activity. Endocrinology 1979;104:736-43.
9. Maurer RA. Relationship between estradiol, ergocryptine, and thyroid hormone: effects on prolactin synthesis and prolactin messenger ribonucleic acid levels. Endocrinology 1982;110:1515-20.
10. Pichon MF, Bression D, Peillon F, Milgrom E. Estrogen receptors in human pituitary adenomas. J Clin Endocrinol Metab 1980;51:897-902.
11. Kajtar T, Tomkin GH. Emergency hypophysectomy in pregnancy after induction of ovulation. BMJ 1971;4:88-90.
12. Swyer GI, Little V, Harries BJ. Visual disturbance in pregnancy after induction of ovulation. BMJ 1971;4:90-1.
13. Falconer MA, Stafford-Bell MA. Visual failure from pituitary and parasellar tumours occurring with favourable outcome in pregnant women. J Neurol Neurosurg Psychiatry 1975;38:919-30.
14. Lamberts SW, Seldenrath HJ, Kwa HG, Birkenhager JC. Transient bitemporal hemianopsia during pregnancy after treatment of galactorrhea-amenorrhea syndrome with bromocriptine. J Clin Endocrinol Metab 1977;44:180-4.
15. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68:412-8.
16. March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1981;139:835-44.
17. Koppelman MC, Jaffe MJ, Rieth KG, Caruso RC, Loriaux DL. Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases. Ann Intern Med 1984;100:115-21.
18. Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril 1987;48:67-71.
19. Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 1979;31:363-72.
20. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999;44:1121-6.
21. Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 1994;121:473-7.
22. Bronstein MD. Prolactinomas and pregnancy. Pituitary 2005;8:31-8.
23. Weiss MH. Treatment options in the management of prolactin-secreting pituitary tumors. Clin Neurosurg 1986;33:547-52.
24. Vance ML, Evans WS, Thorner MO. Drugs five years later. Bromocriptine. Ann Intern Med 1984;100:78-91.
25. Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 1982;247:1589-91.
26. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331:904-9.
27. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10:333-7.
28. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996;14:228-38.
29. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996;135:413-20.
30. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003;349:2035-41.
31. Hopp L, Weisse AB, Iffy L. Acute myocardial infarction in a healthy mother using bromocriptine for milk suppression. Can J Cardiol 1996;12:415-8.
32. Kovacs K, Ryan N, Horvath E, Singer W, Ezrin C. Pituitary adenomas in old age. J Gerontol 1980;35:16-22.
33. Serri O, Kuchel O, Buu NT, Somma M. Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab 1983;56:255-9.
34. Erroi A, Bassetti M, Spada A, Giannattasio G. Microvasculature of human micro- and macroprolactinomas. A morphological study. Neuroendocrinology 1986;43:159-65.
35. Molitch ME. Pituitary tumors and pregnancy. Growth Horm IGF Res 2003;13(Suppl A):S38-S44.
36. Belchetz PE, Carty A, Clearkin LG, Davis JC, Jeffreys RV, Rae PG. Failure of prophylactic surgery to avert massive pituitary expansion in pregnancy. Clin Endocrinol 1986;25:325-30.
37. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-40.
38. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86:5256-61.
39. Brodsky JB, Cohen EN, Brown BW Jr, Wu ML, Whitcher C. Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 1980;138:1165-7.